Pfizer Inc. (NYSE:PFE) ranks among the best retirement stocks to buy now. On May 5, BofA Securities boosted its price ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Pfizer shares have gained ground since a report over the weekend said that activist investor ...

Pfizer Inc. (NYSE:PFE) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Pfizer Inc. (NYSE:PFE) is one of the largest pharmaceutical companies in the world. It operates in the weight ...

Pfizer PFE is facing one of the steepest patent cliffs in the large-cap pharma space. The company expects a significant ...

Wilsey Asset Management disclosed the purchase of Pfizer shares valued at an estimated $2.9 million during the third quarter, according to an SEC filing released Wednesday. According to a filing with ...

Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own. The drugmaker's pipeline could lead to even more important brand-new ...

(Reuters) -Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted sweetened bids, with Metsera saying Novo's $10 billion offer is ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. The big US drugmaker pointed to another drop in ...

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

Pfizer Inc. secures Metsera, Inc. acquisition, outbidding Novo Nordisk, with a deal valued up to $86.25 per share including milestone CVRs. The board favored PFE's offer due to higher certainty of ...